Kornimate/medical-research-clean huggingface dataset:
diffusion-weighted mri for liver metastasis

Conditions: Colorectal Cancer; Colon Cancer Liver Metastasis; Malignant Neoplasm of Rectum Metastatic to Liver

Summary: the dream study will assess the diagnostic accuracy of diffusion-weighted mri in combination with other imaging modalities (multiparametric mri and ct scan) in determining the true status of disappearing liver metastasis (dlm) detected after conversion systemic therapy for unresectable or borderline resectable colorectal liver metastasis (crlm).

the advancements of systemic and local therapies for complex crlm have led to the increased incidence of dlms. it is hypothesized that dw-mri imaging could distinguish between a metastasis not completely sterilized by conversion therapy and a sterilized scar (non-viable tumor). if this can be demonstrated, the use of dw-mri could make a significant impact on the surgical decision making process by providing surgeons a more reliable guide to decide whether to leave behind or to resect/ablate a site of dlm. most importantly, this surgical choice can also have a significant impact on patient outcomes as it may impact the risk of local recurrence and the need for re-operation.the possibility of improving surgical management of complex crlm is foreseen if the benefit of observing or resecting small residual metastases and dlms is clarified through a multi-center and international prospective study.

Eligibility criteria:
inclusion criteria for eligibility: 1. contrast-enhanced thorax, abdomen and pelvic ct scan (with at least portal venous phase for the liver) at diagnosis and right before surgery are available 2. multiparametric mri at baseline and right before surgery are available (t1/t2, dw-mri and contrast enhanced mri). 3. who performance status of 0 or 1 4. previous treatments (chemotherapy, surgery) for primary, liver and extra-hepatic metastases are allowed. 5. no other malignancies in the 3 years prior to study entry with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage t1a or t1b prostate cancer gleason score ≤ 6, and basal/squamous cell carcinoma of the skin 6. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study criteria for enrollment 1. conversion therapy is either being given or completed 2. patient is suitable for hepatic resection based on the assessment of mdt composed of at least an expert liver/colorectal surgeon, gastrointestinal (gi) radiologist and oncologist prior to any liver surgery 3. hepatic resection is scheduled to take place within 8 weeks of latest imaging exclusion criteria: 1. contraindications to any contrast agents for ct and mri or mri procedure 2. pregnancy 3. significant comorbidity that will preclude either conversion therapy or surgery

Keywords: unresectable colorectal liver metastasis diffusion weighted mri disappearing liver metastasis
loading regimen，serum trough concentrations，efficacy and safety in pneumonia patients with gram-positive infections

Conditions: Pneumonia Gram-Positive Bacterial

Summary: this was a retrospective study that all teicoplanin-treated adult patients with gram-positive infections admitted to zhengzhou central hospital affiliated to zhengzhou university from february 2015 to august 2016.

1. patients and protocol this was a retrospective study that all teicoplanin-treated adult patients with gram-positive infections admitted to zhengzhou central hospital affiliated to zhengzhou university from february 2015 to august 2016. patients were included who met the following criteria: (1) age≥18 years, (2) duration of teicoplanin therapy≥5 days, (3) written informed consent was obtained from each patients. patients were excluded who fulfilled any of the following criteria: (1) patients who were allergy to teicoplanin, (2) pregnant women, (3) patients with hematopoietic function, (4) patients unable to evaluate efficacy and safety. this study was approved by the research ethics committee of the zhengzhou central hospital affiliated to zhengzhou university. 2. treatment regimen and groups according to clcr and teicoplanin loading dose regimen, all patients were divided into four groups. group a (clcr≥60ml/min) : teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by mrsa or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d. group b (40 ml/min≤clcr\ 30 mg/l, the maintenance dosage was increased or decreased appropriately up to target cmin range. clcr values for male and female were calculated based on the following equations, respectively.

Eligibility criteria:
inclusion criteria: * age≥18 years * duration of teicoplanin therapy≥5 days * written informed consent was obtained from each patients exclusion criteria: * patients who were allergy to teicoplanin * pregnant women * patients with hematopoietic function * patients unable to evaluate efficacy and safety
xerotic dermatitis in aged people

Conditions: Itching Symptoms; Xerotic Dermatitis

Summary: the purpose of the study is to assess the the effect of the study product on itching symptoms associated with xerotic dermatitis in aged population


Eligibility criteria:
inclusion criteria: * aged from 70 years * with xerotic dermatitis, clinically assessed , * at least on the anterior part of lower and/or upper limbs, * presenting itching xerotic dermatitis evolving from at least 3 weeks * intensity of itching ≥ 4 on vas (0-10) at th inclusion time * with mmse score ≥ 20 dating less than 6 months * affiliated to a social security system, or is a beneficiary (as applicable in the national regulation) exclusion criteria: * criteria related to pathologies * severe form of other dermatitis requiring either systemic treatment -- itching xerotic dermatitis from iatrogenic origins * dermatological disease other than xerotic dermatitis which could interfere with the assessment, * systemic disease that may generate xerotic dermatitis and /or pruritus * immunosuppression condition, * history of serious disease considered by the investigator hazardous for the patient or incompatible with the study. * criteria related to treatment - use of treatment which could interfere with the evaluation of the disease or the course of the disease * criteria related to the population * ongoing participation to another clinical trial or participation in the previous month before the inclusion * patient under guardianship or trusteeship

Keywords: associated aged population
pain relief effect of low-intensity continuous ultrasound stimulator for knee arthritis

Conditions: Osteoarthritis, Knee

Summary: the goal of this clinical trial is to test low-intensity continuous ultrasound stimulator(licus) for patients suffering from knee arthritis. it aims to evaluate the pain relief effect of licus. 35 participants were recruited, treated by licus on the knee joint for 5 minutes, 3 times a day for 4 weeks. this study has single group and is for a before and after comparison of clinical treatment.

subject: 35 osteoarthritis patients evaluation measure: visual analogue scale (vas), mcmaster universities osteoarthritis index (womac) method: a total of 35 subjects were selected in consideration of the dropout rate of 20%. selected subjects were treated as a single group without randomization, and an appropriate amount of gel was applied to the knee oa pain area for 4 weeks. a blinded evaluation at baseline and after treat-ment was made. primary outcome was pain on movement assessed by the vas index. secondary outcomes consisted of the womac scores.

Eligibility criteria:
inclusion criteria: * patients aged 40 to 60 years with pain due to oa of the knee and able to walk voluntarily * those who have more than one osteophyte in the tibiofemoral joint on radiographic findings (kellgren-lawrence gradesⅱ,ⅲ) * at visit 1 (screening) and visit 2, the pain status during knee oa activity was 100 mm pain vas, as a result, those who are over 40mm * if the kellgren \& lawrence grades are the same, target the one with the higher 100mm pain vas * patients who are willing or able to follow the doctor's instructions, including joint movements * persons who can comply with concomitantly permitted drugs, prohibited drugs, and relief drugs * persons who can maintain the same exercise and activity during the clinical trial period * fully understand the purpose and procedure of this clinical trial exclusion criteria: * those who have a history of rheumatoid arthritis or gouty arthritis or who have peripheral pain other than the knee joint patient. * those with fractures or dislocations on simple radiological examination. * those who are identified, or those with a similar risk of neuromuscular disease * those who have participated in other clinical trials within 6 months of participating in clinical trials. * patients with severe pain in the knee joint other than angular deformity, instability, and index knee in the knee joint * patients with other tumors other than degenerative knee arthrosis * persons with systemic symptoms that may affect knee pain * pregnant and lactating women
exceptional responders with solid tumor cancer to chemotherapy

Conditions: Solid Tumor Neoplasms

Summary: this is an observational study enrolling patients with solid tumor cancers to identify genomic expression differences between exceptional responders and non-responders to standard of care chemotherapy. data analysis of the gene expression profile of the exceptional responders compared to non-responders will define genomic patterns that may help understand their response to chemotherapy.

this is an observational study of patients with solid tumor cancer to identify genomic expression differences obtained from their circulating tumor cells between exceptional responders and non-responders to standard of care chemotherapy. this study requires a 10 ml heparinized peripheral blood sample from each study participant at the time of enrollment to isolate, enrich and profile circulating tumor cells. data analysis of the gene expression profile will define genomic patterns using nearest template prediction for a predetermined panel of therapeutic agents based on standard of care. chemotherapy selection is physician-choice. information regarding disease progression will be gathered. data analysis will be performed in study participants in the setting of ongoing disease progression.

Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of solid tumor carcinoma. * patient is treatment-naïve or currently receiving chemotherapy. * ecog performance status (any). exclusion criteria: * hiv positive on antiretroviral therapy * pregnant or lactating * prior organ allograft * any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment

Keywords: solid tumor cancer
understanding the role of oral microbiota in behçet's disease (behcetbiot)

Conditions: Behçet Disease; Physiopathology; Microbiota; Oral Microbiota

Summary: behçet's disease (bd) is a systemic vasculitis that affects, especially, young people. although its etiology remains unexplained, data suggest that the inflammatory response during bd results from a disruption of the homeostasis of innate and adaptive immune responses in genetically predisposed people. the microbiota could play a triggering role in bd, in particular the salivary and dental plaque microbiota. the aim of the behçetbiot study is therefore to establish microbial profiles of dental plaque, pathological (on the mouth ulcer) and non-pathological mucous membrane, salivary and digestive and to compare them with control subjects not suffering from bd, related to the first degree, of the same socio-cultural level and to determine whether dysbiosis is correlated with a local and systemic pro-inflammatory response, by measuring salivary level of pro-inflammatory cytokines and blood level of crp, fibrinogen, orosomucoïd and haptoglobin, and to compare them with controls.

all patients and their controls are sampled for stool, saliva, dantal plaque, oral mucosa, genital mucosa and blood during an annual follow-up visit or if they are hospitalised. plaque, oral mucosa, genital mucosa salivary and blood will be collected during an annual follow-up visit. for stool samples, the collection material will be provided to the patient and they will be able to take the sample at home and bring it to the clinic, or send them via a carrier within 3 days. all the samples related to the study will be taken in the internal medicine in clermont-ferrand (france) or pitie salpêtrière, department of internal medecine, paris,france or ophthalmology departments in clermont-ferrand. all sample will be stocked in biological center in clermont-ferrand before analyze. microbiota analyzes will be realise at m2ish laboratoty, inflammatory cytokines will be analyze in clermont-ferrand immunology laboratory, and pro-inflammatory parameters will be analyse in biochimy laboratory in clermont-ferrand.

Eligibility criteria:
inclusion criteria: * patients who meet the international criteria for the classification of behçet's disease, revised in 2013) * patient who had developed the disease in the 5 years preceding the study. exclusion criteria: * pregnant or breastfeeding women, or women who may be pregnant or breastfeeding. * subject placed under judicial protection. * patient had received antibiotic or probiotic or symbiotic therapy in the 6 weeks preceding inclusion
a study to assess the effect of tocilizumab + methotrexate on prevention of structural joint damage in patients with moderate to severe active rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: this 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (mtx) in patients with moderate to severe active rheumatoid arthritis. patients will be randomized to receive tocilizumab 4 mg/kg iv, tocilizumab 8 mg/kg iv or placebo iv, every 4 weeks. all patients will also receive methotrexate, 10-25 mg/week. the anticipated time on study treatment is 1-2 years and the target sample size is 500+ individuals. after completion of the 2 year study participants could participate in the optional 3 year open label extension phase (year 3 to 5).


Eligibility criteria:
inclusion criteria: * adult patients at least 18 years of age with moderate to severe active ra for at least 6 months; * inadequate response to a stable dose of mtx; * patients of reproductive potential must be using reliable methods of contraception. exclusion criteria: * major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study; * prior treatment failure with an anti-tumor necrosis factor agent; * women who are pregnant or breast-feeding.
combination of ab-life probiotic plus monacolin k to reduce blood cholesterol

Conditions: Hypercholesterolemia

Summary: this randomized study evaluates the effectiveness of a nutraceutical combining billion colony forming units (cfu) of three l. plantarum strains (cect7527, cect7528 and cect7529) and 10 mg of monacolin k in reducing blood cholesterol.

cardiovascular diseases (cvds) are the number 1 cause of death globally, and retention of low-density lipoprotein cholesterol (ldl-c) and similar cholesterol-rich lipoproteins containing apolipoprotein b (apob) within the arterial wall is a key initiating event in cvds. statins are the mainstay of pharmacological cholesterol-reduction therapy. however, a significant proportion of patients report some degree of statin intolerance, which typically fade away when the statin is switched, discontinued or the dosage reduced. a growing attention has been devoted to the correction of increased ldl-c levels through the use of dietary supplements, either because some patients have milder forms of hypercholesterolemia or as an alternative to statins in patients who may have experienced or are worried of side effects. nutraceutical combinations are increasingly used in clinical practice. in this pilot randomized study, we sought to evaluate of the effect on ldl-c and other blood lipid parameters of a nutraceutical combining red yeast rice extract (also known by its scientific name monascus purpureus) containing 10 mg of monacolin k, plus 1 billion colony forming units (cfu) of the ab-life probiotic formula. the later is composed of three l. plantarum strains, namely cect7527 (also known as kabp011™), cect7528 (also known as kabp012™) and cect7529 (also known as kabp013™).

Eligibility criteria:
inclusion criteria: * total cholesterol (tc) ≥200 mg/dl and statin-naïve or having recently stopped statin treatment because of statin intolerance. exclusion criteria: * history of cardiovascular events or alcohol abuse, presence of diabetes, chronic advanced kidney disease, thyroid disorders, hepatic disorders, familial hypercholesterolemia or immunosuppression * body mass index (bmi) ≤ 18.5 or ≥40 kg/m2 * use of antibiotics within 4 weeks of study initiation, current use of other probiotics, lipid-lowering medications, corticoids, beta-blockers or calcium channel blockers, thiazide diuretics, estrogen replacement therapy * pregnant or lactating women * patients with other severe disease that could interfere with the results of the study. * patients not agreeing to maintain their usual physical activity throughout the study.

Keywords: probiotic lactobacillus monacolin k monascus purpureus
deb-tace+ralox-haic vs deb-tace for large hcc

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: this study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (deb-tace) combined with hepatic artery infusion chemotherapy (haic) with oxaliplatin and raltitrexed (ralox-haic) versus deb-tace alone for unresectable large hepatocellular carcinoma (hcc).

this is a multicenter randomized study to evaluate the efficacy and safety of deb-tace plus ralox-haic (deb-tace+haic) compared with deb-tace alone for unresectable large hcc (\>7cm). 130 patients with unresectable large hcc (\> 7cm) will be enrolled in this study. the patients will receive either deb-tace+haic or deb-tace using an 1:1 randomization scheme. in the deb-tace+haic arm, the microcatheter will be reserved at the main hepatic tumor-feeding artery and chemotherapy drugs (ralox-based regimen) will be intra-arterially administered though the microcatheter. in the deb-tace arm, patients will be treated with deb-tace alone. the treatments can be repeated on demand (at a 4-week interval usually) based on the evaluation of follow-up laboratory and imaging examination by the multidisciplinary team. during follow-up, the potential resectability of the tumor will be assessed by the multidisciplinary team (mdt). once the tumors become resectable, curative surgical resection will be recommended for the patients. the primary end point of this study is progression-free survival (pfs). the secondary endpoints are tumor response (objective response rate and disease control rate), overall survival (os) , and adverse events (aes).

Eligibility criteria:
inclusion criteria: * hcc confirmed by histology/cytology or diagnosed clinically. * at least one measurable intrahepatic target lesion. * the largest tumor size \> 7 cm. * tumor recurrence after curative treatment (hepatectomy or ablation) is eligible for enrollment. * child-pugh score 5-7. * ecog performance status ≤ 1. * adequate organ and hematologic function with platelet count ≥75×10\^9/l, leukocyte \>3.0×10\^9/l, neutrophil count ≥1.5×10\^9/l, asl and ast≤5×uln, creatinine clearance≤1.5×uln, and prolongation of prothrombin time ≤4 seconds. exclusion criteria: * macrovascular invasion or extrahepatic metastasis. * diffuse hcc. * decompensated liver function, including: ascites, bleeding from gastroesophageal varices, and hepatic encephalopathy. * previous palliative treatments, including tace, transcatheter arterial embolization, haic, radiation therapy, systemic therapy. * organ (heart and kidneys) dysfunction, unable to tolerate tace or haic treatment. * history of other malignancies. * uncontrollable infection. * history of hiv. * gastrointestinal bleeding within 30 days, or other bleeding\> ctcae grade 3. * history of organ or cells transplantation. * pregnant or lactating patients.

Keywords: hepatocellular carcinoma transarterial chemoembolization drug-eluting beads hepatic artery infusion chemotherapy oxaliplatin raltitrexe
cognitive remediation and social skills training in schizophrenia

Conditions: Schizophrenia; Schizoaffective

Summary: the purpose of this study is to examine whether patients who participate in cognitive remediation prior to a skills training program learn and perform the skills better than patients who do not participate in cognitive remediation.

subjects are 40 stable outpatients with schizophrenia or schizoaffective disorder who are receiving medication and routine follow-up care at community clinics in san antonio, texas. patients receive baseline assessments and then are randomly assigned to either cognitive remediation (cr) or keyboarding skills (ks) for a period of 8 weeks. following 8 weeks of treatment in either cr or ks, all patients participated in social skills training (sst) for a period of 8 weeks. assessments conducted by raters blinded to treatment condition are repeated following either remediation or control treatment, and again following sst. treatment groups cognitive remediation (cr) -- the cr program is based upon teaching techniques developed within educational psychology that promote intrinsic motivation and task engagement. the program uses existing computer software packages (e.g., oregon trail) with engaging story lines or activities, and built-in reinforcement of correct responses to help patients with schizophrenia develop attention, memory, planning, and problem-solving skills. cr is delivered in a computer lab setting with a facilitator present to assist patients. keyboarding skills (ks) -- control treatment: the control treatment is an engaging self-paced software program designed to teach typing skills. ks is delivered in a computer lab setting with a facilitator present. both the ks and cr are administered in small groups of three to five patients each. social skills training (sst) -- sst is a manual-driven, behavioral rehabilitation program teaching basic conversation and social problem-solving skills (bellack et al., 1997). sst runs for 8 weeks and is conducted in small groups that meet twice weekly.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia/schizoaffective disorder * currently receiving treatment with an atypical antipsychotic medication * between the ages of 18 and 60 years * speak english as their primary language * has at least a 6th grade level of reading (wrat) exclusion criteria * no current diagnosis of substance abuse or dependence * no documented history of head injury, epilepsy or mental retardation.

Keywords: schizophrenia cognitive remediation social skills training psychosocial